2025 Annual Report of Independent Director (Wang Jianfeng)

2025 Annual Report of Independent Director (Wang Jianfeng)

I, Wang Jianfeng, as an independent director of Shanghai Kaixin Separation Technology Co., Ltd. (hereinafter referred to as "the Company"), have diligently fulfilled my responsibilities in accordance with the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Management Measures for Independent Directors of Listed Companies, the Listing Rules of the Shenzhen Stock Exchange for Growth Enterprises, the Self-Regulatory Guidelines No. 2 for Listed Companies on the Shenzhen Stock Exchange, as well as the Company’s Articles of Association and the Independent Director Work System. In 2025, I have fully exercised my role as an independent director, safeguarding the overall interests of the Company and the legitimate rights and interests of all shareholders, especially minority shareholders. The following is my report on the performance of my duties as an independent director in 2025:

I. Basic Information of the Independent Director

Wang Jianfeng, female, born in 1971, holds a master's degree, is a Chinese national, and has no permanent residency abroad. From 2007 to 2011, I served as the Chief Financial Officer of Jiateng Polymer Materials Co., Ltd.; from 2011 to 2012, I was the Risk Control Director at Changjiang Growth Capital Investment Co., Ltd.; since 2012, I have been the Chairwoman of Bangmeng Huijun Digital Technology (Shanghai) Co., Ltd. I have served as an independent director of Shanghai Medicy Bio-Pharmaceutical Co., Ltd. since January 2025 and as an independent director of this Company since January 2024. During the reporting period, my position complies with the independence requirements stipulated in Article 6 of the Management Measures for Independent Directors of Listed Companies, and there are no circumstances affecting my independence.

II. Annual Performance of Duties

(A) Attendance at Board and Shareholder Meetings

In 2025, the Company held 7 board meetings and 4 shareholder meetings. The operations of the board and shareholder meetings complied with legal procedures. With a prudent attitude, I voted in favor of all proposals submitted at each board meeting and did not express any objections or abstentions. My attendance at the board and shareholder meetings during the reporting period is as follows: